External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer

Abstract

BackgroundSetting priorities for the funding of new anti-cancer agents is becoming increasingly complex. The funding of adjuvant trastuzumab for breast cancer has brought this dilemma to the fore. In this paper we review external factors that may influence decision-making bodies and present a case study of media response in Ontario, Canada to adjuvant trastuzumab for breast cancer.MethodsA comprehensive search of the databases of Canadian national and local newspapers and television was performed. Articles pertaining to trastuzumab in adjuvant breast cancer as well as 17 other anti-cancer drugs and indications were retrieved. The search period was from the date when individual trial results were announced to the date funding was made available in Ontario.ResultsDuring the 2.6 months between the release of the trastuzumab results to funding approval in Ontario, we identified 51 episodes of media coverage. For the 17 other drugs/indications (7 breast and 10 non-breast), the median time to funding approval was 31 months (range 14–46). Other recent major advances in oncology such as adjuvant vinorelbine/cisplatin for resected NSCLC and docetaxel for advanced prostate cancer received considerably less media attention (17 media reports for each) than trastuzumab. The median number of media reports for breast cancer drugs was 4.5 compared to 2.5 for non-breast cancer drugs (p = 0.56).ConclusionPriority-setting for novel anti-cancer agents is a complex process that tries to ensure fair use of constrained resources to fund therapies with the best evidence of clinical benefit. However, this process is subject to external factors including the influence of media, patient advocates, politicians, and industry. The data in this case study serve to illustrate the significant involvement one (or all) of these external factors may play in the debate over priority-setting.

Research Output and the Public Health Burden of Cancer: Is There Any Relationship?

“…Priority-setting within oncology is known to be a complex process subject to external factors, including the influence of media, patient advocates, politicians, and industry 18 . We believe that the substantial range in research investment across cancer sites (that is, from CA$599/death in bladder cancer to CA$14,329/death in breast cancer) is important and speaks to the need for discussion within the oncology community about whether those allocations represent optimal and equitable use of resources.…”

Therapies For Advanced CancersPose A Special Challenge For Health Technology Assessment Organizations In Many Countries

“…11 The pan-Canadian Oncology Drug Review does not publicly acknowledge using explicit costeffectiveness thresholds. However, authorities have reimbursed providers for the use of certain cancer drugs, despite their relatively poor costeffectiveness.…”

Bevacizumab for Advanced Breast Cancer: Hope, Hype, and Hundreds of Headlines

“…The effect the media has is complex and can influence patients [9,10], physicians [4,[11][12][13][14], and possibly policy makers [15][16][17]. The objective of our study was to categorize and analyze the newspaper reports surrounding bevacizumab's use in metastatic breast cancer and to assess whether the nature of this reporting varied with time.…”